Long-term progression-free survival in metastatic uveal melanoma after chemoimmunotherapy and consolidation thermoablation.
Al-Jamal
Rana'a T
RT
Eskelin
Sebastian
S
Pyrhönen
Seppo
S
Kivelä
Tero
T
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D017115:Catheter Ablation / Q000379:methods*; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000008:administration & dosage; D018572:Disease-Free Survival; D006801:Humans; D007167:Immunotherapy; D007370:Interferon Type I / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000401:mortality* / Q000556:secondary / Q000628:therapy; D008130:Lomustine / Q000008:administration & dosage; D008279:Magnetic Resonance Imaging; D008297:Male; D008545:Melanoma / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D008875:Middle Aged; D011379:Prognosis; D011994:Recombinant Proteins; D016896:Treatment Outcome; D014604:Uveal Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D014750:Vincristine / Q000008:administration & dosage
D007370:Interferon Type I; D011994:Recombinant Proteins; D001761:Bleomycin; D014750:Vincristine; D008130:Lomustine; D003606:Dacarbazine